Objective
The More Medicines for Tuberculosis (MM4TB) consortium evolved from the highly successful FP6 project, New Medicines for TB (NM4TB), that delivered a candidate drug for clinical development two years ahead of schedule. Building on these firm foundations and exploiting its proprietary pharmacophores, MM4TB will continue to develop new drugs for TB treatment. An integrated approach will be implemented by a multidisciplinary team that combines some of Europe's leading academic TB researchers with two major pharmaceutical companies and four SMEs, all strongly committed to the discovery of anti-infective agents. MM4TB will use a tripartite screening strategy to discover new hits in libraries of natural products and synthetic compounds, while concentrating on both classical and innovative targets that have been pharmacologically validated. Whole cell screens will be conducted against Mycobacterium tuberculosis using in vitro and ex vivo models for active growth, latency and intracellular infection. Hits that are positive in two or more of these models will then be used for target identification using functional genomics technologies including whole genome sequencing and genetic complementation of resistant mutants, yeast three hybrid, click chemistry and proteomics. Targets thus selected will enter assay development, structure determination, fragment-based and rational drug design programs; functionally related targets will be found using metabolic pathway reconstruction. Innovative techniques, based on microfluidics and array platforms, will be used for hit ranking, determining rates of cidality and confirming mechanism of action. Medicinal chemistry will convert leads to molecules with drug-like properties for evaluation of efficacy in different animal models and late preclinical testing.
Fields of science
- natural sciencesphysical sciencesclassical mechanicsfluid mechanicsmicrofluidics
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsproteomics
- medical and health sciencesbasic medicinemedicinal chemistry
- medical and health sciencesclinical medicinepneumologytuberculosis
- natural sciencesbiological sciencesgeneticsgenomes
Call for proposal
FP7-HEALTH-2010-single-stage
See other projects for this call
Funding Scheme
CP-IP - Large-scale integrating projectCoordinator
1015 Lausanne
Switzerland
See on map
Participants (26)
Participation ended
560024 Bangalore
751 05 Uppsala
See on map
27100 Pavia
See on map
CB2 1TN Cambridge
See on map
Participation ended
E1 4NS London
75724 Paris Cedex 15
See on map
119071 Moscow
See on map
35122 Padova
See on map
814 99 Bratislava
See on map
8200 Veszprem
See on map
NR4 7UH Norwich
See on map
560012 Bangalore
See on map
560066 Bangalore
See on map
13100 Vercelli
See on map
94010 Burlingame Ca
See on map
48940 Leioa
See on map
41126 Modena
See on map
50009 Zaragoza
See on map
8092 Zuerich
See on map
07749 Jena
See on map
91380 Chilly Mazarin
See on map
7701 Rondebosch
See on map
Participation ended
1025 Saint Sulpice
75654 Paris
See on map
1015 Lausanne
See on map
65929 Frankfurt Am Main
See on map